Navigation Links
Life Technologies Announces First Quarter 2011 Results
Date:4/26/2011

March 31, 2011.   (8)  Add back loss on early retirement of debt.   (9)  Adjust for gain on divestiture of equity investments.   (10)  Adjust for gain on impaired security recovery of $6.7 million and gain on foreign currency related to joint venture divestiture of $1.0 million offset by loss on discontinuance of cash flow hedge of $12.9 million and joint venture purchase accounting adjustment of $1.2 million for the three months ended March 31, 2010.(11)  Non-GAAP tax differs from GAAP tax expense primarily because certain acquisition related costs such as: restructuring; amortization of acquired intangibles; depreciation of acquired property, plant, and equipment and; fair market value adjustments to contingent consideration liabilities associated with certain acquisitions. In addition, GAAP net income includes interest expense with related income tax benefits as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options but excluded for Non-GAAP purposes. These deductions produce a GAAP only tax benefit which is added back for Non-GAAP presentation.(12)  Add back noncash charges for purchase accounting inventory revaluations and depreciation of purchase accounting property, plant and equipment revaluations attributable to non-controlling interest, net of tax benefit.   LIFE TECHNOLOGIES CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFor the three monthsended March 31,(in thousands)(unaudited)

20112010Net income$
93,579$  91,507Add back amortization and share-based compensation

98,15593,472Add back depreciation

30,31731,479Balance sheet changes

(96,785)(80,655)Other noncash adjustments

(10,215)(64,980)Net cash provided by operating activities

115,05170,823Capital expenditures

(16,576)(30,285)Free cash flow98,47540,538Net cash provided by (used in) investing activities

(34,287)424,363Net
'/>"/>

SOURCE Life Technologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. RainDance Technologies Appoints Olex Vice President, System Development
3. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
4. Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing
5. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
8. Anthill Technologies Announces Agreement With Zafgen
9. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
10. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
11. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
(Date:1/22/2015)... 22. 2015  Varian Medical Systems (NYSE: VAR ), ... for its commitment to sustainability with inclusion on a prestigious ... highest ranked healthcare equipment company among the Corporate Knights Global ... Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Tech provides veteran business leadership to deliver new ideas to market. ... ... www.lgeexecs.com [LGE Execs], an Austin based firm formed to ... agreement with the Texas Tech University System (TTUS). The agreement will ...
... - Dr. Yong Shi of Stevens Institute of ... his project titled "MEMS Umbrella-Shaped Actuator with Active ... on scientific/technical merit for three years and will ... is to design, fabricate and test an umbrella-shaped ...
... SAN FRANCISCO, Calif., Sept. 2 Anesiva,Inc. (Nasdaq: ... M.D. has joined,the company as senior vice president ... clinical and regulatory functions., "Bill brings to ... management products, and a medical background in,anesthesiology," said ...
Cached Biology Technology:LGE Execs Teams with Texas Tech to License Advancements in Agriculture, Health and Life Sciences 2LGE Execs Teams with Texas Tech to License Advancements in Agriculture, Health and Life Sciences 3Dr. Yong Shi awarded NSF grant 2Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer 2
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... medical device currently used for intestinal research, the colonsope, ... method has been developed, inspired by the way in ... received her PhD degree from TU Delft based on ... extremely difficult area to navigate through with a medical ...
... drug tamoxifen (Nolvadex®), which can become less effective over ... along with a second drug, according to new research ... Institute (NCI), part of the National Institutes of Health, ... 11, 2006, issue of Cancer Cell*. , Tamoxifen has ...
... Herceptin is borne by other patients whose treatment has to ... week’s BMJ. , New guidance from the National Institute for ... breast cancer, but it provides no extra funding and does ... extra money. This leaves medical staff with difficult decisions to ...
Cached Biology News:Like a snail through the intestinal canal 2Restoring tamoxifen sensitivity in resistant breast cancer cells 2Other patients bear the real cost of Herceptin 2
... DMW143 taken from the SMZ line is a ... production and testing. It is available with a ... or a space-saving compact base (N2GG). This microscope ... and a projector all at the same time ...
... Reagent optimized for siRNA applications, contains magnetic ... the nucleic acid of interest. Exploiting magnetic ... then rapidly drawn towards and delivered into ... MATra-si Reagent can be used for adherent ...
...
... The TNT Coupled Reticulocyte Lysate Systems(a,b,c,d) ... in vitro translations: a single-tube, coupled ... greatly simplify the process and reduce ... vitro translation results. Standard rabbit reticulocyte ...
Biology Products: